Archive for July, 2014

(QUMU) for Good Brings Video for Mobile Securely to the Enterprise

Qumu (NASDAQ:QUMU), the leading enterprise video platform provider, today announced the availability of Qumu for Good Technology™ customers. As a Good Mobile Alliance member and certified on the Good Dynamics® Secure Mobility Platform, Qumu for Good brings the power of the industry leading Qumu Video Control Center and its mobile capabilities to the enterprise, while meeting the security requirements of enterprise IT with Good Technology’s secure mobility solutions.

“Video as a communication, collaboration and enablement tool is growing rapidly within the enterprise,” said Dave Yockelson, vice president of product marketing. “So is the need to access this content from mobile devices. With many of these video assets containing sensitive information, IT departments can rest easy knowing videos are delivered optimally with Qumu and secured with Good Technology.”

Qumu optimizes mobile video through an extension of the Video Control Center – providing central management of video assets and intelligent distribution to all mobile devices. This enables employees to get the content they need, when and where they need it, without taxing network infrastructures. Qumu Video Control Center manages all the backend content preparation and network intelligence automatically to ensure each user gets the specific version of a video that is appropriate for their device and network connection.

Securely delivering video to any device has always been a priority for Qumu. With Qumu for Good, enterprises running on Good Dynamics can securely deliver mobile video communication, collaboration, and education to their employees around the globe.

Good Technology is the leading solutions provider for enterprise-grade mobile security and compliance. With the Good Dynamics Secure Mobility Platform, companies facing the challenges of rapid mobile device adoption, expanding BYOD policies, and mobile application usage now have the ability to empower their employees and meet end-user needs without introducing unnecessary security risks.

“Companies are increasingly turning to mobile and video to increase employee productivity and engagement,” said Matt Sturges, vice president of Good Dynamics Ecosystem at Good Technology. “Today’s companies need professional-grade mobile applications designed with security in mind in order to tap the benefits of the mobility wave, and Qumu’s mobile video application uniquely addresses this need.”

The Qumu applications are available on the Apple app store and Google Play™, and are also available in the Good Marketplace.

For more information about Qumu, visit: http://www.Qumu.com

Download the Qumu for Good app here: https://community.good.com/marketplace.jspa

About Qumu

Qumu Corporation (NASDAQ:QUMU) provides the industry leading Video Content Management and Delivery solution businesses use to create, manage, secure, distribute and measure the success of their videos. Qumu’s innovative solutions release the power in video to engage and empower employees, partners and clients. With Qumu, thousands of organizations around the world realize the greatest possible value from video and other rich content they create and publish. Whatever the audience size, viewer device or network configuration, Qumu solutions are how business does video.

©2014 Good Technology Corporation and its related entities. All use is subject to license terms posted at www.good.com/legal. All rights reserved. GOOD, GOOD TECHNOLOGY, the GOOD logo, GOOD FOR ENTERPRISE, GOOD FOR GOVERNMENT, GOOD FOR YOU, GOOD DYNAMICS, SECURED BY GOOD, GOOD MOBILE MANAGER, GOOD CONNECT, GOOD SHARE, and GOOD DYNAMICS APPKINETICS are trademarks of Good Technology Corporation and its related entities. All third-party trademarks, trade names, or service marks are the property of their respective owners. Good’s technology and products are protected by issued and pending U.S. and foreign patents.

Thursday, July 31st, 2014 Uncategorized Comments Off on (QUMU) for Good Brings Video for Mobile Securely to the Enterprise

(RAND) Announces Net Asset Value of $4.43, New Investments

  • Net Asset Value increases to $4.43 per share, a 1.8% ($.08) increase from prior quarter
  • Seven investments totaling $4 million represents busiest quarter in recent history
  • Notable investments during the quarter included a total of $1.85 million in Empire Genomics, LLC and Teleservices Solutions Holdings, LLC and $2.18 million in follow-on investments in five portfolio companies
  • BinOptics continues to grow its etched facet technology laser solutions
  • Total assets of $37.7 million

BUFFALO, N.Y., July 31, 2014  — Rand Capital Corporation (“Rand”) (Nasdaq:RAND) announced June 30, 2014 net asset value of $28.4 million, or $4.43 per share, representing a $.08 increase per share from March 31, 2014, and a $.50 per share increase from June 30, 2013.

Portfolio activity during the second quarter of 2014 included:

  • Empire Genomics, LLC (Buffalo, NY) (www.empiregenomics.com) – $600,000 debt investment. Empire Genomics is a molecular diagnostics company that develops and offers a comprehensive menu of assay services for use in diagnosing and guiding precise therapeutic treatments for patients.
  • Teleservices Solutions Holdings, LLC (TSH) (Montvale, NJ) (www.ipacesetters.com) – $1,250,000 equity investment in Class B and Class C shares. TSH is a customer contact center specializing in customer acquisition and retention for selected industries.
  • Chequed.com, Inc. (Saratoga Springs, NY) (www.chequed.com) – $350,000 follow-on equity investment in additional Series A Preferred shares. Chequed.com is a predictive employee selection and development software company for the Human Resource sector.
  • Knoa Software, Inc. (New York, NY) (www.knoa.com) – $479,155 equity investment in Series B-1 Preferred shares. Knoa software monitors, measures and manages how end-users use enterprise software applications, improving software performance and its users’ experiences.
  • Mercantile Adjustment Bureau, LLC (Williamsville, NY) (www.mercantilesolutions.com) – $150,000 follow-on debt investment. Mercantile is a full service accounts receivable management and collection company.
  • SciAps, Inc. (Woburn, MA) (www.sciaps.com) – $500,000 follow-on investment in additional Series A Preferred shares. SciAps is a hand held analytical instrumentation company specializing in durable, field tested, portable instruments utilizing LIBS and Raman spectroscopy. These devices are used in law enforcement, and the mining, pharmaceutical and other industries.
  • SocialFlow, Inc. (New York, NY) (www.socialflow.com) – $750,000 follow-on equity investment in Series B-1 Preferred shares. SocialFlow provides instant analysis of current opportunities on social networks using proprietary, predictive analytic algorithms to determine best time for its customers to publish or advertise.

BinOptics Corporation (Ithaca, NY) (www.binoptics.com), a Deloitte 2013 Technology Fast 500 winner as one of North America’s fastest growing companies, continues to deploy its unique etched facet technology into the world-wide marketplace exploiting the need for optical connectivity and semi-conductor laser products in the rapidly growing markets of smart phones, cellular backhaul, data centers and fiber to the home.

Allen F. Grum, President of Rand Capital, stated, “We continue to deploy capital as evidenced by $1.85 million investments in new companies and $2.18 million in portfolio companies. We also revalued our investment in BinOptics Corporation to reflect its improved financial performance as reflected in record sales profits and units shipped in the recent quarters. We continue to evaluate our portfolio and opportunities for liquidity events and hope to share these with you in the future.”

Safe Harbor Statement

Information contained in this release, other than historical information, should be considered forward-looking, and may be subject to inherent uncertainties in predicting future results and conditions. These statements reflect the Corporation’s current beliefs and are subject to a number of risk-factors, including: general economic conditions which affect Rand and our portfolio companies’ operations; valuation and illiquid nature of the portfolio investments; high degree of risk from investing in private companies; the regulated environment in which we operate; the amount of debt resulting from borrowing funds from the SBA; dependency upon key management for investment decisions; and the competitive market for investment opportunities and fluctuations in quarterly results. Please see the Corporation’s Form 10-Q, Item 1A, previously filed with the Securities and Exchange Commission for a detailed discussion of the risks and uncertainties associated with the Corporation’s business.  Except as otherwise required by Federal securities laws, Rand Capital Corporation and Rand Capital SBIC, Inc. undertakes no obligation to update or revise forward-looking statements for new events and uncertainties.

ABOUT RAND CAPITAL

Rand Capital is a publicly held Business Development Company (BDC), and its wholly owned subsidiary is licensed by the Small Business Administration (SBA) as a Small Business Investment Company (SBIC). Rand and its subsidiary provide capital and managerial expertise to small and medium sized private companies primarily located in the Northeast U.S. Rand is traded on the NASDAQ under the symbol “RAND” and is headquartered in Buffalo, NY. www.randcapital.com

CONTACT: Investor Contact:
         Allen F. Grum
         President
         716-853-0802
         pgrum@randcapital.com
Thursday, July 31st, 2014 Uncategorized Comments Off on (RAND) Announces Net Asset Value of $4.43, New Investments

(FCEL) Announces Strategic Financing Agreements With NRG Energy

  • Company sells 14.6 million shares of common stock to NRG at $2.39 per share for proceeds of $35 million
  • Company enters into $40 million revolving construction / term financing facility with NRG for project development
  • Financing commitments support and reinforce existing strategic relationship with NRG

DANBURY, Conn., July 31, 2014  — FuelCell Energy, Inc. (Nasdaq:FCEL), a global leader in the design, manufacture, operation and service of ultra-clean, efficient and reliable fuel cell power plants, announced a broadening and deepening of the existing relationship with NRG Energy (NYSE:NRG) including a $35.0 million investment in FuelCell Energy common stock by NRG Energy and the establishment of a new $40.0 million revolving construction and term loan facility by NRG Energy for FuelCell Energy to use for project development. NRG Energy now owns approximately 17.0 million shares of the Company’s common stock, or 6.0 percent, including 2.4 million shares owned prior to this transaction.

“We believe that clean distributed power generation from fuel cells will be one of the key technologies that drive our country toward a cleaner energy future,” said Mauricio Gutierrez, Chief Operating Officer, NRG Energy, Inc. “We want to actively participate in the construction of FuelCell Energy power plants in order to promote choice and meet the specific needs of our existing and future customers.”

“The continuing support of NRG Energy is further validation of our power generation solutions and our business model,” said Chip Bottone, Chief Executive Officer, FuelCell Energy, Inc. “We are working closely with the NRG team and have developed a strong pipeline of megawatt-class combined heat and power projects. These agreements strengthen the Company’s liquidity position and are expected to accelerate deployment of multi-megawatt fuel cell projects in the U.S.”

FuelCell Energy sold 14,644,352 shares of its common stock to NRG Energy in a private placement at a price of $2.39 per share, the closing market price for the stock on July 29, 2014, for total proceeds to the Company of $35.0 million. The transaction closed on July 30, 2014. FuelCell Energy intends to use the net proceeds from the offering for project development, project finance, working capital support and general corporate purposes. The terms of the equity transaction include a warrant giving NRG the right to purchase an additional 2.0 million shares of common stock at a price $3.35 per share. The warrant has a term of three years.

In addition to the common stock investment, NRG Energy has extended a $40 million revolving construction and term financing facility for the purpose of accelerating project development by FuelCell Energy and its subsidiaries. The Company’s project finance subsidiaries may draw on the facility to finance the construction of projects through the commercial operating date (COD) of the power plants. The Company has the option to continue the financing term for each project after COD for a maximum term of five years per project. The interest rate is 8.5 percent per annum for construction-period financing and 8.0 percent thereafter.

“A key advantage of this new credit facility is that it enables FuelCell Energy to undertake project development and then sell the fully operational power plants to long term project investors,” said Michael Bishop, Chief Financial Officer, FuelCell Energy, Inc. “This facility should help us accelerate the pace of adoption and also improve our margins as the access to credit will allow us to execute more quickly, thereby minimizing construction-period financing and allowing us to optimize the ownership and financing of projects once they are completed.”

Draws under the credit facility are subject to traditional project finance conditions precedent, including the existence of a power purchase agreement (PPA) with the end-user of the power and customary project documentation, economic performance and compliance with applicable laws and regulations. Projects must be located in the United States or pre-designated neighboring countries including Canada and some Caribbean nations. FuelCell Energy is expected to construct the projects and operate and maintain them for the term of the corresponding PPAs pursuant to arms’-length agreements with the project companies, whether or not the project companies continue to be subsidiaries of FuelCell Energy.

FuelCell Energy’s stationary fuel cell power plants efficiently and cleanly provide electricity and usable high quality heat near the point of use through an electrochemical process. The power plants are fuel flexible, capable of operating on clean natural gas, on-site renewable biogas, or directed biogas. The combination of near-zero pollutants, modest land-use needs and quiet operating nature facilitates locating the Company’s power plants in urban locations.

About NRG

NRG is leading a customer-driven change in the U.S. energy industry by delivering cleaner and smarter energy choices, while building on the strength of the nation’s largest and most diverse competitive power portfolio. A Fortune 250 company, NRG creates value through reliable and efficient conventional generation while driving innovation in solar and renewable power, electric vehicle ecosystems, carbon capture technology and customer-centric energy solutions. NRG retail electricity providers serve almost 3 million residential and commercial customers throughout the country. More information is available at www.nrg.com.

About FuelCell Energy

Direct FuelCell® power plants are generating ultra-clean, efficient and reliable power at more than 50 locations worldwide. With more than 300 megawatts of power generation capacity installed or in backlog, FuelCell Energy is a global leader in providing ultra-clean baseload distributed generation to utilities, industrial operations, universities, municipal water treatment facilities, government installations and other customers around the world. The Company’s power plants have generated more than 2.6 billion kilowatt hours of ultra-clean power using a variety of fuels including renewable biogas from wastewater treatment and food processing, as well as clean natural gas. For more information, please visit www.fuelcellenergy.com

See us on YouTube

Direct FuelCell, DFC, DFC/T, DFC-H2 and FuelCell Energy, Inc. are all registered trademarks of FuelCell Energy, Inc. DFC-ERG is a registered trademark jointly owned by Enbridge, Inc. and FuelCell Energy, Inc.

Cautionary Language

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements with respect to the Company’s anticipated financial results and statements regarding the Company’s plans and expectations regarding the continuing development, commercialization and financing of its fuel cell technology and business plans. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause such a difference include, without limitation, changes to projected deliveries and order flow, changes to production rate and product costs, general risks associated with product development, manufacturing, changes in the regulatory environment, customer strategies, unanticipated manufacturing issues that impact power plant performance, changes in critical accounting policies, potential volatility of energy prices, rapid technological change, competition, and the Company’s ability to achieve its sales plans and cost reduction targets, as well as other risks set forth in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements contained herein speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based.

CONTACT: FuelCell Energy, Inc.
         Kurt Goddard, Vice President Investor Relations
         203-830-7494
         ir@fce.com

         NRG Energy, Inc.
         Karen Cleeve, Corporate Communications
         609-524-4608

         Chad Plotkin, Investor Relations
         609-524-4526
Thursday, July 31st, 2014 Uncategorized Comments Off on (FCEL) Announces Strategic Financing Agreements With NRG Energy

(HALO) FDA Advisory Committee Panel Provides Favorable Recommendation on HyQvia

Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter’s investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has a favorable risk/benefit profile.

HyQvia was approved in Europe in 2013 for adults (≥18 years) with primary immunodeficiency syndromes and myeloma or chronic lymphocytic leukaemia (CLL) with severe secondary hypogammaglobulinaemia and recurrent infections.

Data presented at today’s advisory committee meeting included a review of the preclinical and clinical data supporting the HyQvia application. The FDA will consider the recommendation from the BPAC in its review of Baxter’s amendment to the Biologics License Application (BLA) submitted in December 2013. The company expects the FDA response in the third quarter.

”We are hopeful that the positive support for HyQvia is the next step toward providing a new treatment option for patients with primary immunodeficiency in the United States. We look forward to working closely with the FDA as it completes its review,” said Ludwig Hantson, Ph.D., president of Baxter BioScience.

”Today’s BPAC vote underscores the strength of the HyQvia data and our rHuPH20 platform,” commented Dr. Helen Torley, President and Chief Executive Officer of Halozyme. ”Our rHuPH20 platform has been studied in thousands of patients spanning multiple disease states and a number of approved products.”

HyQvia was approved by the European Commission for EU member states in 2013 and is currently being prescribed in several European countries, including Germany, Netherlands, Sweden, Norway, Denmark, Ireland and Italy.

About HyQvia

HyQvia is a product consisting of human normal immunoglobulin (IG 10%) and recombinant human hyaluronidase (licensed from Halozyme Therapeutics). The IG provides the therapeutic effect and the recombinant human hyaluronidase facilitates the dispersion and absorption of the IG administered subcutaneously, increasing its bioavailability. The IG is a 10% solution that is prepared from human plasma consisting of at least 98% IgG, which contains a broad spectrum of antibodies.

HyQvia is indicated in Europe as replacement therapy in adults (≥18 years) with primary immunodeficiency syndromes and in myeloma or chronic lymphocytic leukaemia (CLL) with severe secondary hypogammaglobulinaemia and recurrent infections.

Important Risk Information

HyQvia should not be used by patients with a hypersensitivity to human immunoglobulins, especially in very rare cases of IgA deficiency when the patient has antibodies against IgA. HyQvia should not be used by patients with a systemic hypersensitivity to hyaluronidase or recombinant human hyaluronidase. HyQvia should not be used by patients with a hypersensitivity to any of the excipients, including glycine.

HyQvia must not be given intravenously.

HyQvia should not be used by women who are pregnant, or are planning to become pregnant, or are breast-feeding.

Patients should be closely monitored and carefully observed for any adverse reactions throughout the infusion period, particularly patients starting with HyQvia treatment. In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped. The treatment required depends on the nature and severity of the adverse reaction. In case of shock, standard medical treatment for shock should be implemented.

Thromboembolic events (e.g. myocardial infarction, cerebral vascular accident, deep vein thrombosis, and pulmonary embolism), renal dysfunction/failure, aseptic meningitis syndrome, and hemolysis have been observed with IG 10% administered intravenously and cannot be excluded with use of HyQvia. Thrombotic events and haemolysis have also been reported in association with the subcutaneous administration of immunoglobulin products.

Human normal immunoglobulin and human serum albumin (stabilizer of the recombinant human hyaluronidase) are produced from human plasma and may carry a risk of transmitting infectious agents.

About Baxter International Inc.

Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

About Halozyme Therapeutics

Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company’s research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme’s pipeline addresses therapeutic areas, including oncology, diabetes, and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, and Baxter. Halozyme is headquartered in San Diego. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

This release includes forward-looking statements concerning HyQvia, including expectations with regard to pending regulatory review in the US. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; additional clinical results; changes in laws and regulations; product quality or supply or patient safety issues; and other risks identified in each of the company’s most recent filings on Form 10-K and other SEC filings, all of which are available on their respective websites. Neither Baxter nor Halozyme undertakes to update its forward-looking statements.

Thursday, July 31st, 2014 Uncategorized Comments Off on (HALO) FDA Advisory Committee Panel Provides Favorable Recommendation on HyQvia

(PSUN) Announces Resignation of SVP Christine Lee, Comments on Second Quarter Guidance

ANAHEIM, Calif., July 31, 2014 — Pacific Sunwear of California, Inc. (Nasdaq:PSUN) (the “Company”) today announced the resignation of Christine Lee, its Senior Vice President of Women’s Merchandising and Design.  Brieane Breuer, who joined PacSun in 2007 and is the Company’s current Vice President of Women’s Design, will assume the additional responsibilities of women’s merchandising on an interim basis.

Ms. Breuer received her Master’s Degree in fashion design and styling from Istituto Marangoni and over the past 13 years has held various merchandising and design roles at high-end fashion brands such as Valentino, as well as at Abercrombie & Fitch.

The Company also stated that it expects its non-GAAP loss from continuing operations per diluted share for the second quarter of fiscal 2014 to be generally in line with analysts’ consensus estimates of $(0.03), which compares favorably to the Company’s previously issued non-GAAP guidance of $(0.08) to $(0.02).

“Sales trends across the business have generally improved in both June and July with Men’s again on track to achieve a positive comp for the second quarter,” said Gary H. Schoenfeld, President and CEO of Pacific Sunwear. “Based on the strength of our brand assortment, along with our leadership position with the Men’s jogger for back-to-school, we expect Men’s to continue its positive momentum as we look ahead to the third quarter.”

Mr. Schoenfeld continued: “With respect to our Women’s business, we are focused on four key areas:  (1) Increasing the penetration of brands, which further differentiates us from our competitors in the mall; (2) Leveraging the vision of our design team even more by leading with new trends; (3) Strengthening our non-apparel business; and (4) Driving growth online.”

“I appreciate all of the efforts Christine has put forth over the past four years to help re-position the PacSun business,” said Mr. Schoenfeld. “I am eager to work even more closely with Brie and the rest of our Women’s team to successfully tackle our key initiatives. I am excited by several recent creative concepts coming from our design team and optimistic that the Women’s business can soon get back to positive comps as well.”

About Pacific Sunwear of California, Inc.

Pacific Sunwear of California, Inc. and its subsidiaries (collectively, “PacSun” or the “Company”) is a leading specialty retailer rooted in the action sports, fashion and music influences of the California lifestyle. The Company sells a combination of branded and proprietary casual apparel, accessories and footwear designed to appeal to teens and young adults. As of July 31, 2014, the Company operates 618 stores in all 50 states and Puerto Rico. PacSun’s website address is www.pacsun.com.

Pacific Sunwear Safe Harbor

This press release contains “forward-looking statements” including, without limitation, the statements made by the Company and Mr. Schoenfeld in the third, fourth, fifth and sixth paragraphs. In each case, these statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company intends that these forward-looking statements be subject to the safe harbors created thereby. These statements are not historical facts and involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Uncertainties that could adversely affect the Company’s business and results include, among others, the following factors: increased sourcing and product costs; adverse changes in U.S. and world economic conditions generally; adverse changes in consumer spending; changes in consumer demands and preferences; adverse changes in same-store sales; higher than anticipated markdowns and/or higher than estimated selling, general and administrative costs; currency fluctuations; competition from other retailers and uncertainties generally associated with apparel retailing; merchandising/fashion risk; lower than expected sales from private label merchandise; reliance on key personnel; economic impact of natural disasters, terrorist attacks or war/threat of war; shortages of supplies and/or contractors as a result of natural disasters or terrorist acts, which could cause unexpected delays in store relocations, renovations or expansions; reliance on foreign sources of production; and other risks outlined in the Company’s filings with the Securities and Exchange Commission (“SEC”), including but not limited to the Company’s Annual Report on Form 10-K for the fiscal year ended February 1, 2014, and subsequent periodic reports filed with the SEC. Historical results achieved are not necessarily indicative of future prospects of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update or revise any such forward-looking statements to reflect events or circumstances that occur after such statements are made. Nonetheless, the Company reserves the right to make such updates from time to time by press release, periodic report or other method of public disclosure without the need for specific reference to this press release. No such update shall be deemed to indicate that other statements not addressed by such update remain correct or create an obligation to provide any other updates.

About non-GAAP Financial Measures

The accompanying press release dated July 31, 2014, contains a non-GAAP financial measure. This non-GAAP financial measure includes a forward-looking estimate of the Company’s non-GAAP loss from continuing operations per diluted share for the second quarter of fiscal 2014. Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures do not reflect a comprehensive system of accounting, differ from GAAP measures with the same names and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. The Company computes non-GAAP financial measures using the same consistent method from quarter to quarter and year to year. The Company may consider whether other significant items that arise in the future should be excluded from the non-GAAP financial measure. The Company believes that this non-GAAP financial measure provides meaningful supplemental information regarding the Company’s operating results primarily because it exclude amounts that are not considered part of ongoing operating results when planning and forecasting and when assessing the performance of the organization, individual operating segments or its senior management. In addition, the Company believes that non-GAAP financial information is used by analysts and others in the investment community to analyze the Company’s historical results and in providing estimates of future performance and that failure to report non-GAAP measures, could result in confusion among analysts and others and create a misplaced perception that the Company’s results have underperformed or exceeded expectations.

CONTACT: Michael W. Kaplan
         Chief Financial Officer
         (714) 414-4003
Thursday, July 31st, 2014 Uncategorized Comments Off on (PSUN) Announces Resignation of SVP Christine Lee, Comments on Second Quarter Guidance

(QKLS) Opens One New Hypermarket

DAQING, China, July 31, 2014  — QKL Stores Inc. (the “Company”) (Nasdaq: QKLS), a leading regional supermarket chain in Northeastern China, today announced the opening of one new hypermarket.

The Company’s 48th new store, situated in Daqing City, Heilongjiang, was opened on July 18, 2014. The hypermarket is located in a remolded shopping mall in the center of the commercial district of the east city, serving about 500,000 potential customers. This hypermarket occupies approximately 8,400 sq. meters of gross space.

Mr. Zhuangyi Wang, Chairman and CEO, said, “We are delighted to open another store in our “home” city of Daqing city, where the QKL brand is widely recognized. Our business has developed rapidly since we opened our first store in Daqing City in 1999 and we believe the value and convenience of our stores in Daqing has resulted in strong customer loyalty in the local community. Our new store will provide the opportunity to introduce our broad assortment of high quality products and unique shopping experience to a new group of customers in Daqing City. We are pleased to open our third store this year.”

About QKL Stores Inc.:

Based in Daqing, China, QKL Stores, Inc. is a leading regional supermarket chain company operating in Northeast China. QKL Stores sells a broad selection of merchandise, including groceries, fresh food, and non-food items, through its retail supermarkets, hypermarkets and department stores; the company also has its own distribution centers that service its supermarkets. For more information, please access the Company’s website at: www.qklstoresinc.com.

Safe Harbor Statement

Certain statements in this release and other written or oral statements made by or on behalf of the Company are “forward looking statements” within the meaning of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The forward looking statements are subject to a number of risks and uncertainties including market acceptance of the Company’s services and projects and the Company’s continued access to capital and other risks and uncertainties. The actual results the Company achieves may differ materially from those contemplated by any forward-looking statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the date of such statements.

Contact Information:

In China:
Mike Li, Investor Relations
+86-459-460-7987
Thursday, July 31st, 2014 Uncategorized Comments Off on (QKLS) Opens One New Hypermarket

(IPWR) Secures Multi-Year Purchase Agreement With Sharp Electronics

AUSTIN, TX–(Jul 30, 2014) – Ideal Power Inc. (NASDAQ: IPWR), a developer of a disruptive power conversion technology, is pleased to announce that it has signed a multi-year purchase agreement with Sharp Electronics Corporation (hereafter “Sharp”) whereby Sharp will utilize Ideal Power’s 30kW battery converter in its SmartStorage systems. Ideal Power has received an initial order from Sharp under this agreement, and it expects order volumes to scale along with Sharp’s SmartStorage business.

Sharp’s SmartStorage systems use onsite battery energy storage that can reduce monthly utility demand charges for commercial and industrial building owners. Demand charges are the fastest growing part of utility bills for commercial customers and in some cases can reach half of a company’s monthly utility bill. Both California and New York are already positioned as attractive early markets for the SmartStorage solution, with other states expected to follow. GreenTech Media projects that 600MW of new commercial storage will be installed in the United States by 2020 with the primary benefit of reducing demand charges. For additional information on Sharp’s SmartStorage systems, which was announced formally yesterday, please visit https://www.sharpsmartstorage.com/.

“After evaluating a number of power converter options for Sharp’s SmartStorage System, we ultimately selected Ideal Power’s 30kW battery converter based on its favorable combination of features and performance. We have been testing the converters for some time both in laboratory and commercial deployment settings, and are very pleased with the performance, reliability and ease of use,” said Carl Mansfield, General Manager of Sharp’s Energy Systems and Services Group.

Ideal Power’s 30kW battery converter provides both battery charger and inverter functions at high efficiency in a compact, modular and easy-to-install solution that lowers installed system cost. It is based on the company’s patented Power Packet Switching Architecture™ (PPSA) that provides electrical isolation without the use of a bulky and expensive transformer. Among the many benefits of PPSA is the unique ability to reduce the weight, size, cost and efficiency loss compared to conventional systems.

“Sharp is a global leader in photovoltaic systems whose entry into the market for commercial battery energy storage systems is a meaningful validation for both the potential size and relative timing of this market opportunity,” said Dan Brdar, Chief Executive Officer, Ideal Power. “We are pleased to support Sharp’s SmartStorage system in delivering cost effective solutions for commercial buildings in order to reduce utility demand charges, and believe this multi-year purchase agreement is confirmation of Ideal Power’s leading technology competence in this burgeoning vertical.”

About Ideal Power Inc.
Ideal Power Inc. (NASDAQ: IPWR) has developed a novel, patented power conversion technology called Power Packet Switching Architecture™ (PPSA). PPSA improves the size, cost, efficiency, flexibility and reliability of electronic power converters. PPSA can scale across several large and growing markets, including solar photovoltaic generation, electrified vehicle charging, and commercial grid storage. Ideal Power also has a licensing-based, capital-efficient business model that can enable it to address these markets simultaneously. Ideal Power has won multiple grants for its PPSA technology, including a $2.5 million grant from the Department of Energy’s Advanced Research Projects Agency – Energy (ARPA-E) program, and market-leading customers are incorporating PPSA as a key component of their systems. For more information, visit www.IdealPower.com.

Safe Harbor Statement
All statements in this release that are not based on historical fact are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, whether the patents for our technology provide adequate protection and whether we can be successful in maintaining, enforcing and defending our patents, whether demand for our products, which we believe are disruptive, will develop and whether we can compete successfully with other manufacturers and suppliers of energy conversion products, both now and in the future, as new products are developed and marketed. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.

Ideal Power Media Contact:
Mercom Communications
Wendy Prabhu
1.512.215.4452
www.mercomcapital.com
Email Contact

Ideal Power Inc. Investor Relations Contact:
MZ North America
Matt Hayden
1.949.259.4986
www.mzgroup.us
Email Contact

Wednesday, July 30th, 2014 Uncategorized Comments Off on (IPWR) Secures Multi-Year Purchase Agreement With Sharp Electronics

(TSRA) and Micron Technology Announce New Tech, Patent License Agreements

Tessera Technologies, Inc. (NASDAQ: TSRA) (“Tessera” or the “Company”) and Micron Technology, Inc. (“Micron”) (NASDAQ: MU) announced today the execution of new, multiyear technology and patent license agreements. In addition to the new patent license agreement, Tessera’s wholly-owned subsidiary Invensas Corporation will license its Multi-Die Face-Down (xFDTM) semiconductor packaging technology to Micron and cooperate with Micron on the manufacturing of Micron products that incorporate xFD technology. As part of the agreements, Tessera and Micron will also explore other possible joint development efforts.

Tessera’s Chief Executive Officer Tom Lacey praised the agreements. “We are delighted to reach new long-term agreements with Micron that build on our existing relationship. We are thrilled to be working closely with one of the most successful and innovative semiconductor companies on the planet,” Lacey said. “We have continued to develop innovative, next-generation technologies that we seek to commercialize with world-class partners like Micron. We look forward to working with Micron to commercialize high performance multi-chip xFD DRAM and other products.”

“We are pleased to reach agreement with Tessera, including a patent license and a technology agreement relating to Tessera’s xFD packaging technology,” said Mark Durcan, Micron’s Chief Executive Officer. “We look forward to discussing further joint development opportunities with Tessera.”

The specific terms and conditions of the agreements are confidential and have not been disclosed by the companies.

Safe Harbor Statement

This document contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected, particularly with respect to the new technology and patent license agreements with Micron, the xFD manufacturing cooperation with Micron, possible joint development efforts with Micron, the commercialization of xFD products, and the Company’s development of next-generation technologies. Material factors that may cause results to differ from the statements made include the plans or operations relating to the businesses of the Company; any need to spend more cash and/or incur greater charges than anticipated in connection with the DOC restructuring, workforce reduction, facility closures and related activities; any need to undertake further restructuring activities; market or industry conditions; changes in patent laws, regulation or enforcement, or other factors that might affect the Company’s ability to protect or realize the value of its intellectual property; the expiration of license agreements and the cessation of related royalty income; the failure, inability or refusal of licensees to pay royalties; initiation, delays, setbacks or losses relating to the Company’s intellectual property or intellectual property litigations, or invalidation or limitation of key patents; fluctuations in operating results due to the timing of new license agreements and royalties, or due to legal costs; the risk of a decline in demand for semiconductors and products utilizing FotoNation technologies; failure by the industry to use technologies covered by the Company’s patents; the expiration of the Company’s patents; the Company’s ability to successfully complete and integrate acquisitions of businesses; the risk of loss of, or decreases in production orders from, customers of acquired businesses; financial and regulatory risks associated with the international nature of the Company’s businesses; failure of the Company’s products to achieve technological feasibility or profitability; failure to successfully commercialize the Company’s products; changes in demand for the products of the Company’s customers; limited opportunities to license technologies due to high concentration in the markets for semiconductors and related products and smartphone imaging; and the impact of competing technologies on the demand for the Company’s technologies. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. The Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended Dec. 31, 2013, and its Quarterly Report on Form 10-Q for the quarter ended Mar. 31, 2014, include more information about factors that could affect the Company’s financial results. The Company assumes no obligation to update information contained in this press release. Although this release may remain available on the Company’s website or elsewhere, its continued availability does not indicate that the Company is reaffirming or confirming any of the information contained herein.

About Tessera Technologies, Inc.

Tessera Technologies, Inc. and its subsidiaries generate revenue from licensing to manufacturers and other implementers that use the Company’s technology in areas such as mobile computing and communications, memory and data storage, and 3-D Integrated Circuit technologies. For more information call 1.408.321.6000 or visit www.tessera.com.

Tessera, the Tessera logo, FotoNation, the FotoNation logo and Invensas Corporation are trademarks or registered trademarks of affiliated companies of Tessera Technologies, Inc. in the United States and other countries. All other company, brand and product names may be trademarks or registered trademarks of their respective companies.

About Micron Technology, Inc.

Micron Technology, Inc., is a global leader in advanced semiconductor systems. Micron’s broad portfolio of high-performance memory technologies—including DRAM, NAND and NOR Flash—is the basis for solid state drives, modules, multichip packages and other system solutions. Backed by more than 35 years of technology leadership, Micron’s memory solutions enable the world’s most innovative computing, consumer, enterprise storage, networking, mobile, embedded and automotive applications. Micron’s common stock is traded on the NASDAQ under the MU symbol. To learn more about Micron Technology, Inc. visit www.micron.com.

Wednesday, July 30th, 2014 Uncategorized Comments Off on (TSRA) and Micron Technology Announce New Tech, Patent License Agreements

(IPWR) Secures Multi-Year Purchase Agreement With Sharp Electronics

AUSTIN, TX–(Jul 30, 2014) – Ideal Power Inc. (NASDAQ: IPWR), a developer of a disruptive power conversion technology, is pleased to announce that it has signed a multi-year purchase agreement with Sharp Electronics Corporation (hereafter “Sharp”) whereby Sharp will utilize Ideal Power’s 30kW battery converter in its SmartStorage systems. Ideal Power has received an initial order from Sharp under this agreement, and it expects order volumes to scale along with Sharp’s SmartStorage business.

Sharp’s SmartStorage systems use onsite battery energy storage that can reduce monthly utility demand charges for commercial and industrial building owners. Demand charges are the fastest growing part of utility bills for commercial customers and in some cases can reach half of a company’s monthly utility bill. Both California and New York are already positioned as attractive early markets for the SmartStorage solution, with other states expected to follow. GreenTech Media projects that 600MW of new commercial storage will be installed in the United States by 2020 with the primary benefit of reducing demand charges. For additional information on Sharp’s SmartStorage systems, which was announced formally yesterday, please visit https://www.sharpsmartstorage.com/.

“After evaluating a number of power converter options for Sharp’s SmartStorage System, we ultimately selected Ideal Power’s 30kW battery converter based on its favorable combination of features and performance. We have been testing the converters for some time both in laboratory and commercial deployment settings, and are very pleased with the performance, reliability and ease of use,” said Carl Mansfield, General Manager of Sharp’s Energy Systems and Services Group.

Ideal Power’s 30kW battery converter provides both battery charger and inverter functions at high efficiency in a compact, modular and easy-to-install solution that lowers installed system cost. It is based on the company’s patented Power Packet Switching Architecture™ (PPSA) that provides electrical isolation without the use of a bulky and expensive transformer. Among the many benefits of PPSA is the unique ability to reduce the weight, size, cost and efficiency loss compared to conventional systems.

“Sharp is a global leader in photovoltaic systems whose entry into the market for commercial battery energy storage systems is a meaningful validation for both the potential size and relative timing of this market opportunity,” said Dan Brdar, Chief Executive Officer, Ideal Power. “We are pleased to support Sharp’s SmartStorage system in delivering cost effective solutions for commercial buildings in order to reduce utility demand charges, and believe this multi-year purchase agreement is confirmation of Ideal Power’s leading technology competence in this burgeoning vertical.”

About Ideal Power Inc.
Ideal Power Inc. (NASDAQ: IPWR) has developed a novel, patented power conversion technology called Power Packet Switching Architecture™ (PPSA). PPSA improves the size, cost, efficiency, flexibility and reliability of electronic power converters. PPSA can scale across several large and growing markets, including solar photovoltaic generation, electrified vehicle charging, and commercial grid storage. Ideal Power also has a licensing-based, capital-efficient business model that can enable it to address these markets simultaneously. Ideal Power has won multiple grants for its PPSA technology, including a $2.5 million grant from the Department of Energy’s Advanced Research Projects Agency – Energy (ARPA-E) program, and market-leading customers are incorporating PPSA as a key component of their systems. For more information, visit www.IdealPower.com.

Safe Harbor Statement
All statements in this release that are not based on historical fact are “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, whether the patents for our technology provide adequate protection and whether we can be successful in maintaining, enforcing and defending our patents, whether demand for our products, which we believe are disruptive, will develop and whether we can compete successfully with other manufacturers and suppliers of energy conversion products, both now and in the future, as new products are developed and marketed. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements.

Ideal Power Media Contact:
Mercom Communications
Wendy Prabhu
1.512.215.4452
www.mercomcapital.com
Email Contact

Ideal Power Inc. Investor Relations Contact:
MZ North America
Matt Hayden
1.949.259.4986
www.mzgroup.us
Email Contact

Wednesday, July 30th, 2014 Uncategorized Comments Off on (IPWR) Secures Multi-Year Purchase Agreement With Sharp Electronics

(GALT) Issues Statement on GR-MD-02 Development Program

NORCROSS, Ga., July 30, 2014  — Galectin Therapeutics (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced yesterday results of cohort 2 of its phase 1 clinical trial in patients with NASH with advanced fibrosis. While the results of the clinical trial were positive, the market reacted negatively to this report. We believe the reaction was fueled in part by certain commentary on social media sites and the Internet and we strongly disagree with these interpretations of our data. Our goal in commenting further at this juncture is to provide clarity and a helpful framework for investors on the long-term outlook of the company and our work toward developing potential therapies for NASH and liver fibrosis.

GR-MD-02 is a complex carbohydrate molecule derived from apple pectin material that binds to galectin-3 protein thereby inhibiting its activity. There is a large amount of scientific literature showing galectin-3 is a critical protein in fibrosis. While certain commentators on social media sites have dubbed it a “non-mechanism of action,” this view contradicts many peer reviewed published studies. The phase 1 clinical trial was the first time this molecule was infused into man. Comments on social media about the drug being a “sugar placebo” are misguided and anti-intellectual. GR-MD-02 has been shown to be effective in treating NASH and fibrosis when infused in several animal models, results of which have been reported in peer review scientific journals and presented at international scientific meetings. Based on the pre-clinical data and the enormous need for drugs in an area where there is no therapy, the FDA gave development of GR-MD-02 for NASH with advanced fibrosis Fast Track designation. The importance of galectin-3 in fibrosis and the mechanism of action and the drug action are on a firm scientific foundation.

Certain commentators on social media labeled the second cohort results, “a flop.” This is simply not accurate. The primary endpoints for the phase 1 trial have always been safety and pharmacokinetics and have been successfully met for each cohort completed. The dose of 4 mg/kg was safe and well tolerated and drug levels showed that the drug acted predictably and with a linear increase from the 2 mg/kg dose. While the phase 1 trial is still ongoing, we deem the phase 1 clinical trial a success up to this point.

This phase 1 clinical trial, and in fact all phase 1 clinical trials, are not designed to demonstrate efficacy of a drug. Phase 2 clinical trials are designed to evaluate efficacy of a drug, and our phase 2 clinical trial(s) will follow the completion of this phase 1 trial. Having said this, often a number of exploratory biomarkers are included to determine whether there is some evidence of effect. Exploratory means that there is some scientific evidence that they may provide useful information, but they have not been studied sufficiently to be used as definitive evidence of disease treatment. In fact, in the case of NASH with advanced fibrosis there are no biomarkers that have been shown to change with a short-term treatment. Exploratory biomarker data in our trial do show evidence of some drug effect, but direct comparison of the first and second cohorts was not possible because the timing of the blood draws. Was this a mistake to change the timing of the biomarkers? No, it was not because we are “exploring” how to best use these biomarkers. Because of the differences between the two cohorts, the third cohort will now have 4 evaluations of biomarkers instead of 2 on a larger group of patients. Why didn’t we do more evaluations of biomarkers in the second cohort? Had we done this, and obtained the requisite approval from eight different institutional review boards, the second cohort would have been delayed for up to 2 months. The better approach, in our judgment, was not to spend the time to make these changes and just to make the added blood draws in the third cohort. The critical point is that exploratory biomarkers were included to aid in the design of a phase 2 program that will be focused on showing efficacy, and for this they are serving their purpose.

The question has been asked, “Without clear biomarker changes, how will you choose doses for a phase 2 trial?” We are not dependent on biomarker data for a phase 2 clinical trial. We have a very clear understanding of drug doses and serum drug levels that are associated with a therapeutic effect in animal studies. From the phase 1 clinical trial, we now know that the doses used in man straddle the therapeutic doses used in animals, thus providing the information for choosing doses for a phase 2 clinical trial. The pharmacokinetic data from cohort 3 of the Phase 1 trial are expected to add further to our knowledge about dose selection for the Phase 2 trial (s).

Certain commentators on social media dubbed the drug a “failure” because galectin-3 levels in the blood did not change. This is an incorrect interpretation of our data. As we explained in our webcast when we announced the results of cohort 1 and 2, we do not expect galectin-3 levels in the blood to change with the extent of liver disease. We have shown in animals that there are high levels of galectin-3 in diseased livers, but there is no change in blood levels. Further, we have shown directly that the tissue levels of galectin-3 in the liver are reduced on treatment with GR-MD-02, whereas serum levels are not. Moreover, there are studies from other investigators showing that blood galectin-3 levels do not correlate with liver disease severity in NASH. No change in galectin-3 blood levels is the expected result.

The development program for GR-MD-02 for NASH with advanced fibrosis remains on track. Far from a “flop”, the phase 1 clinical trial, including both cohorts, has been a success. We now have a range of safe doses that can be used in a phase 2 clinical trial and the third cohort will further add to our pharmacokinetic knowledge and guide appropriate dose selection for Phase 2. Upon completion of the third cohort, which has already infused two patients, we will initiate a phase 2 clinical trial program to definitively evaluate the therapeutic potential of this promising therapy using a standard endpoint of liver biopsy to assess efficacy. Planning for the phase 2 trial is underway utilizing the knowledge gained from the Phase 1 trial, to date.

“We are extremely pleased with the progress of our development program in NASH with advanced liver fibrosis,” said Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer of Galectin Therapeutics. “This represents a significant area of unmet medical need, and while there are a number of companies exploring various approaches for therapy, there are no therapies that are near to market, no therapies that have been tested using relevant clinical endpoints, nor any treatments even in phase 3 of development. I am proud of the small, dedicated group of medical and scientific individuals who have worked painstakingly on this program with the hope of bringing an important therapy to patients with NASH with advanced fibrosis. Moreover, we sincerely appreciate the advice, dedication, and support of our investigators and their site personnel and importantly that of their NASH patients who willingly gave their time and energy to help advance our therapy and help others with this this disease.”

On another front, Galectin has been criticized in the media for the use of “an ugly, penny stock promotion scheme.” This is a complete misrepresentation. Small companies often use various approaches to publicize what they are doing and why it may be important for medicine. Because it is costly to have full investor relations functions staffed within the company, companies often use external publicity firms. Emerging Growth LLC was engaged by Galectin to write factual stories related to the company’s programs and attract individuals who would be interested in following the Company’s progress. Emerging Growth has written approximately 13 articles on the company since it began representing Galectin in public relation activities since June 2013, and the company never discloses nonpublic material information to Emerging Growth. The articles were written by Emerging Growth LLC using only information in the public domain and comparing and contrasting Galectin’s program with others in the field. Disclaimers were provided by Emerging Growth LLC that Galectin paid $3500 monthly for this service. The characterization that this practice is a “scheme,” implying an illegal activity, is just not correct. Again, we believe our decision to contract for certain public relations activities, rather than attempting to staff them in-house, is a legal, appropriate and prudent use of our resources.

About Fatty Liver Disease with Advanced Fibrosis

Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, has become a common disease of the liver with the rise in obesity rates, estimated to affect nine to 15 million people, including children, in the U.S. Fatty liver disease is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with fatty liver disease can develop fibrosis, or scarring of the liver, and it is estimated that as many as three million individuals will develop cirrhosis, a severe liver disease where liver transplantation is the only current treatment available. Approximately 6,300 liver transplants are done on an annual basis in the U.S. There are no drug therapies approved for the treatment of liver fibrosis.

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding our drug development program and our clinical trial. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that we may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of GR-MD-02 or any of our other drugs in development. Our current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any of our drugs are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. Regardless of the results of any of our development programs, we may be unsuccessful in developing partnerships with other companies that would allow us to further develop and/or fund any studies or trials. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and finance our continuing operations For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

CONTACT: Galectin Therapeutics Inc.
         Peter G. Traber, MD, 678-620-3186
         President, CEO, & CMO
         ir@galectintherapeutics.com
Wednesday, July 30th, 2014 Uncategorized Comments Off on (GALT) Issues Statement on GR-MD-02 Development Program

(AEGR) Appoints Craig Fraser as Chief Operating Officer

Company Also Appoints Carolina Alarco to President, International and Johanna Sealscott to Vice President, U.S. Sales

CAMBRIDGE, Mass., July 30, 2014  — Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Craig Fraser has been appointed as Chief Operating Officer (COO).

Prior to his appointment as COO, Mr. Fraser served as President, U.S. and International Commercial and Global Manufacturing and Supply Chain at Aegerion, leading the launch of JUXTAPID® in the U.S. Prior to joining Aegerion, Mr. Fraser held a number of commercial leadership positions at other pharmaceutical companies, most recently as Vice President, Global Disease Areas at Pfizer Inc. Prior to that, he was Vice President and Global Business Manager at Wyeth, where he led the institutional business; and Vice President, Commercial and Strategic Operations at Johnson & Johnson.

“Craig’s leadership in the launch of JUXTAPID has demonstrated his ability to build a global commercial organization, solve challenges and foster a motivated and patient-focused culture,” said Marc D. Beer, Chief Executive Officer. “I have great confidence in Craig and believe that in his new role, he will be instrumental in supporting Aegerion’s continued growth through operational excellence.”

Aegerion is also pleased to announce the appointment of Carolina Alarco to President, International and Johanna Sealscott to Vice President, U.S. Sales.

Ms. Alarco previously held the position of Vice President & General Manager, International, building Aegerion’s international team and infrastructure in markets outside the United States and European Union. Prior to Aegerion, Ms. Alarco held various positions within Genzyme Corporation, most recently as Vice-President of Commercial Operations for Latin America for the Renal & Endocrinology Business Units.

Ms. Sealscott joined Aegerion in 2013 as a Regional Sales Director for JUXTAPID. Prior to joining Aegerion, Ms. Sealscott was Senior Sales Director for Optimer Pharmaceuticals, and before that, she was Clinical Sales Director for Intuitive Surgical. Prior to Intuitive, Ms. Sealscott held various sales leadership roles within The Medicines Company.

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.

CONTACT: Aegerion Pharmaceuticals, Inc.
         Amanda Murphy, Manager, Investor & Public Relations
         857-242-5024
Wednesday, July 30th, 2014 Uncategorized Comments Off on (AEGR) Appoints Craig Fraser as Chief Operating Officer

(LOCO) Completion of Initial Public Offering

COSTA MESA, Calif., July 30, 2014  — El Pollo Loco Holdings, Inc. (“El Pollo Loco” and the “Company”) (Nasdaq:LOCO) today announced the completion of its previously announced initial public offering at $15.00 per share. The Company sold a total of 8,214,286 shares of common stock, which included 1,071,429 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. Total net proceeds to the Company from the offering, after deducting underwriter discounts and commissions and estimated offering expenses, were approximately $112.8 million. The issuance and sale of the shares closed on July 30, 2014.

Jefferies, Morgan Stanley and Baird served as joint book-running managers for the offering. William Blair and Stifel served as co-managers for the offering.

A registration statement relating to the shares of common stock of El Pollo Loco was declared effective by the Securities and Exchange Commission (“SEC”) on July 24, 2014. A final prospectus relating to the offering was filed with the SEC and is available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by emailing Prospectus_Department@Jefferies.com, or by calling (877) 547-6340; Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department, or Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 E. Wisconsin Avenue, Milwaukee, WI 53202, by emailing syndicate@rwbaird.com or by calling (800) 792-2473.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor may there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About El Pollo Loco

El Pollo Loco is a differentiated and growing restaurant concept that specializes in fire-grilling citrus-marinated chicken in front of its customers. El Pollo Loco opened its first location on Alvarado Street in Los Angeles, California, in 1980 and has grown to more than 400 company-owned and franchised restaurants in Arizona, California, Nevada, Texas and Utah. The Company’s distinctive menu features its signature product – citrus-marinated fire-grilled chicken – and a variety of Mexican-inspired entrees that the Company and its franchisees create from that chicken.

CONTACT: Investor Contact:
         Fitzhugh Taylor, ICR
         (714) 599-5200
         investors@elpolloloco.com

         Media Contact:
         Liz DiTrapano, ICR
         (646) 277-1226
         liz.ditrapano@icrinc.com
Wednesday, July 30th, 2014 Uncategorized Comments Off on (LOCO) Completion of Initial Public Offering

(AXX) Announces Off-Take Transaction With Glencore

VANCOUVER, BRITISH COLUMBIA–(Jul 29, 2014) – Alderon Iron Ore Corp. (TSX:ADV)(NYSE MKT:AXX) (“Alderon” or the “Company”) is pleased to announce that The Kami Mine Limited Partnership (“Kami LP”), an affiliate of Alderon, has entered into an off-take agreement (the “Off-Take Agreement”) with a subsidiary of Glencore plc (“Glencore”), with respect to an off-take transaction pursuant to which Glencore will acquire all of actual annual production from the Kami Project that has not been allocated to Hebei Iron & Steel Group Co., Ltd.

Under the terms of the Off-Take Agreement, Glencore will be obligated to purchase, upon the commencement of commercial production, 40% of the actual annual production from the Kami Project up to a maximum of 3.2 million tonnes of the first 8.0 million tonnes of iron ore concentrate produced annually at the Kami Project. The term of the Off-Take Agreement will continue until Kami LP has delivered 48.0 million tonnes of iron ore concentrate to Glencore, which is expected to be 15 years after the commencement of commercial production.

“We are extremely pleased to have entered into the Off-Take Agreement with Glencore,” says Mark J. Morabito, Alderon’s Executive Chairman. “Glencore is one of the world’s largest natural resource trading companies and in Alderon’s view, this commitment demonstrates the quality of the Kami Project and its management team.”

“With 100% of the initial production from the Kami Project now committed, we believe this enhances Alderon’s ability to obtain the requisite financing required to commence construction of the Kami Project,” says Tayfun Eldem, Alderon’s President & CEO. “The offtake arrangement with Glencore gives Kami concentrates global exposure and the multi-year agreement serves as another significant de- risking milestone for the Kami Project.”

The market price paid by Glencore will be based on the monthly average price for iron ore sinter feed fines quoted by Platts Iron Ore Index for 62% iron content (plus additional quoted premium for iron content greater than 62%), less a discount equal to 2% of such quoted price.

About Glencore

Glencore is one of the world’s largest global diversified natural resource companies and is one of the biggest companies within the FTSE 100 Index. Glencore’s industrial and marketing activities are supported by a global network of more than 90 offices located in over 50 countries. Its diversified operations comprise of over 150 mining and metallurgical sites, offshore oil production assets, farms and agricultural facilities.

The Metals and Minerals division is focused on iron ore, copper, nickel, zinc/lead, alloys, and alumina/aluminum, with interests in both controlled and non-controlled industrial assets that include mining, smelting, refining and warehousing operations.

About Alderon

Alderon is a leading iron ore development company in Canada with offices in Montreal, Vancouver, St. John’s and Labrador City. The Kami Project, owned 75% by Alderon and 25% by Hebei Iron & Steel Group Co. Ltd. (“HBIS”) through The Kami Mine Limited Partnership, is located within Canada’s premier iron ore district and is surrounded by four producing iron ore mines. Its port handling facilities are located in Sept-Îles, the leading iron ore port in North America. The Alderon team is comprised of skilled professionals with significant iron ore expertise to advance Kami towards production. HBIS is Alderon’s strategic partner in the development of the Kami Project and China’s largest steel producer.

For more information on Alderon, please visit our website at www.alderonironore.com.

ALDERON IRON ORE CORP.

On behalf of the Board

Mark J Morabito, Executive Chairman

Cautionary Note Regarding Forward-Looking Information

This press release contains “forward-looking information” within the meaning of the U.S. Private Securities Litigation Reform Act and Canadian securities laws concerning anticipated developments and events that may occur in the future. Forward-looking information contained in this press release include, but are not limited to, statements with respect to (i) the development of the Kami Project; and (ii) the details of the Off-take Agreement.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance. Forward-looking information contained in this press release is based on certain factors and assumptions regarding, among other things, receipt of governmental and other approvals, the estimation of mineral reserves and resources, the realization of reserve and resource estimates, iron ore and other metal prices, the timing and amount of future exploration and development expenditures, the estimation of initial and sustaining capital requirements, the estimation of labour and operating costs, the availability of necessary financing and materials to continue to explore and develop the Kami Project in the short and long-term, the progress of exploration and development activities, the receipt of necessary regulatory approvals, the estimation of insurance coverage, and assumptions with respect to currency fluctuations, environmental risks, title disputes or claims, and other similar matters. While the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect.

Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include risks inherent in the exploration and development of mineral deposits, including risks relating to changes in project parameters as plans continue to be redefined including the possibility that mining operations may not commence at the Kami Project, risks relating to variations in mineral resources, grade or recovery rates resulting from current exploration and development activities, risks relating to the ability to access rail transportation, sources of power and port facilities, risks relating to changes in iron ore prices and the worldwide demand for and supply of iron ore and related products, risks related to increased competition in the market for iron ore and related products and in the mining industry generally, risks related to current global financial conditions, uncertainties inherent in the estimation of mineral resources, access and supply risks, reliance on key personnel, operational risks inherent in the conduct of mining activities, including the risk of accidents, labour disputes, increases in capital and operating costs and the risk of delays or increased costs that might be encountered during the development process, regulatory risks, including risks relating to the acquisition of the necessary licences and permits, financing, capitalization and liquidity risks, including the risk that the financing necessary to fund the exploration and development activities at the Kami Project may not be available on satisfactory terms, or at all, risks related to disputes concerning property titles and interest, risks related to disputes with Aboriginal groups, environmental risks and the additional risks identified in the “Risk Factors” section of the Company’s Annual Information Form for the most recently completed financial year, which is included in its Annual Report on Form 40-F filed with the U.S. Securities and Exchange Commission (the “SEC”) or other reports and filings with applicable Canadian securities regulators and the SEC. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information is made as of the date of this press release. Except as required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information.

Alderon Iron Ore Corp.
Montreal Office
514-281-9434
514-281-5048
Alderon Iron Ore Corp.
Vancouver Office
604-681-8030
604-681-8039
Alderon Iron Ore Corp.
Evelyn Cox
604-681-8030 ext 223 or 1-888-990-7989
info@alderonironore.com
www.alderonironore.com

Tuesday, July 29th, 2014 Uncategorized Comments Off on (AXX) Announces Off-Take Transaction With Glencore

(CPSS) Realizes A 27% IRR And 2.3X Money From Its Investment In Consumer Portfolio Services

LOS ANGELES, July 29, 2014  — Levine Leichtman Capital Partners (LLCP) announced today that it has successfully exited its investment in Consumer Portfolio Services, Inc. (Nasdaq: CPSS) realizing a 27% IRR and 2.3X money.

CPSS is an independent specialty finance company that provides indirect automobile financing to individuals with past credit problems, low incomes or limited credit histories. The company purchases retail installment sales contracts primarily from franchised automobile dealerships secured by late model used vehicles and, to a lesser extent, new vehicles. CPSS funds these contract purchases on a long-term basis primarily through the securitization markets and services the contracts over their lives.  Its operational headquarters are located in Irvine, California with four additional strategically located servicing branches in Nevada, Virginia, Florida and Illinois.

“We have thoroughly enjoyed our long term partnership with CPSS and its management team led by Chairman and CEO Charles E. Bradley, Jr.  During the past six years, we have seen CPSS deliver on its significant growth in contracts purchased and managed receivable portfolio.  We are very pleased to have been part of the CPSS success story,” said Lauren Leichtman, CEO of LLCP. “We are also pleased to provide a very attractive return to LLCP’s investors through an exit that was facilitated by CPSS excellent access to the capital markets.”

About Levine Leichtman Capital Partners

Levine Leichtman Capital Partners is a private investment firm with offices in Los Angeles, New York, Dallas, Chicago and London. LLCP manages approximately $7.0 billion of institutional capital for investment in U.S. middle market companies. LLCP invests through private equity partnerships and various debt and leveraged loan funds. LLCP is currently making new investments through Levine Leichtman Capital Partners V, L.P., Levine Leichtman Capital Partners SBIC Fund, L.P., and Levine Leichtman Capital Partners Private Capital Solutions, L.P. Prior investments by Levine Leichtman Capital Partners include Santa Cruz Nutritionals, CiCi’s Pizza, Hackney Ladish, and Jon Douglas Real Estate Group.

Tuesday, July 29th, 2014 Uncategorized Comments Off on (CPSS) Realizes A 27% IRR And 2.3X Money From Its Investment In Consumer Portfolio Services

(OPLK) Announces Initiatives to Enhance Shareholder Value

Commences Process to Evaluate Strategic Alternatives for Oplink Connected Business, Including Possible Sale

Authorizes $40 Million Increase to Existing Share Repurchase Program

Initiates $0.05 Quarterly Dividend

Plans to Expand Board of Directors by up to Two Additional Members with Relevant Expertise

Company Also Provides a Preview of its Fourth Quarter Fiscal 2014 Results and Revenue Guidance for First Quarter Fiscal 2015

FREMONT, Calif., July 29, 2014  — Oplink Communications, Inc. (Nasdaq:OPLK), a leading provider of optical communication components, intelligent modules and subsystems, today announced a series of initiatives to further enhance shareholder value.

Those initiatives include the Company’s intent to evaluate strategic alternatives for its Oplink Connected unit, including a possible sale of the business; the authorization of a $40 million increase to its existing share repurchase program; the initiation of a quarterly dividend to shareholders, which will begin with a $0.05 dividend in the first quarter of fiscal 2015; and Oplink’s intent to expand its Board of Directors by up to two members in order to add further industry expertise.

Oplink also today provided a preview of its financial results for its fourth quarter of fiscal year 2014, ended June 29, 2014, and its preliminary revenue guidance for the first quarter of fiscal year 2015, ending September 28, 2014. Details are provided below.

“The initiatives we announced today, along with our strong quarterly financial performance, demonstrate Oplink’s ongoing commitment to driving growth and creating long-term, sustainable value for our shareholders,” said Joe Liu, Chairman and CEO of Oplink. “We regularly evaluate our overall strategy as well as the optimal allocation of capital to maximize value by balancing investment in the business and direct return of cash to shareholders. In addition, we are always open to input from our shareholders, and the steps announced today reflect, in part, constructive conversations we have had with several of our shareholders.”

Decision to Seek Strategic Alternatives for Oplink Connected Business

As the Company continues to focus on driving shareholder value and increasing operational efficiencies, Oplink has commenced a process to seek strategic alternatives for Oplink Connected, including a possible sale of all or part of the business. The Company has retained Cowen and Company, LLC as financial adviser to assist the Board and senior management team in that process. In addition, as a result, Oplink intends to reclassify the operating results of the Oplink Connected business as discontinued operations, beginning in the quarter ending September 28, 2014.

“We continue to believe that the Oplink Connected business has great value, with the most manageable mobile video alarm and secure video conference platform and solutions available,” said Mr. Liu. “However, we recognize that this effort requires substantial resources, and we wish to be responsive to shareholder concerns regarding the impact of the continued spending on our financial results. We believe that separating Oplink Connected can unlock value for both the Connected business and our core optical business.”

Expansion of Stock Repurchase Program

Following a thorough review of the Company’s capital structure and cash flow, the Oplink Board of Directors has authorized an increase of $40 million to its existing stock repurchase program, bringing its current repurchase authorization to $70 million. The Company repurchased $18.2 million of its stock in the quarter ended June 29, 2014 and closed the quarter with cash and marketable securities of $140 million.

“Our strong balance sheet, cash position and solid operating cash flow provide us with the flexibility to continue executing our longer-term strategic initiatives while increasing current returns to shareholders,” said Mr. Liu.

Oplink has repurchased $33.6 million of its stock during the last two fiscal quarters and intends to continue to make repurchases under this expanded authorization through open market purchases, block trades, privately negotiated transactions and/or other means. The actual timing, form and amount of repurchases will be based on management’s evaluation of market conditions, corporate and regulatory requirements and other factors.

Initiation of Quarterly Dividend

Oplink also will initiate a regular quarterly cash dividend to shareholders, which will begin in the first fiscal quarter of 2015 with a dividend of $0.05 per share of the Company’s common stock. The initial dividend will be payable to stockholders of record as of August 14, 2014 and will be paid on August 28, 2014.

Oplink intends to regularly evaluate its capital return policy based on the Company’s financial performance, economic outlook and any other relevant considerations.

Expansion of Oplink Board of Directors

Oplink’s Board of Directors and its Nominating and Corporate Governance Committee (the “Committee”) have commenced a process to expand the Board by up to two additional members. The Board and the Committee are seeking highly qualified individuals with leadership experience in the telecommunications, data communications and/or related industries. The Board has already identified several potential candidates and has engaged the director recruiting services of the National Association of Corporate Directors (NACD) to assist with this process.

Preview of Financial Results and Outlook

Oplink expects to report revenue for the fourth quarter of $51.5 million, up from $48.1 million in the prior quarter, and expects to report non-GAAP net income and earnings per share within the range provided in last quarter’s guidance. On a GAAP basis, the Company expects to report a net loss for the fourth quarter due to a non-cash charge relating to the Oplink Connected business and the decision to seek strategic alternatives for that business. The Company is finalizing its results and will report full financial results for the quarter and the 2014 fiscal year on August 7, 2014.

For the quarter ending September 28, 2014, the Company expects to report revenue of $53 to $57 million.

Fiscal Fourth Quarter Financial Results and Conference Call Information

Oplink will issue a press release reporting full financial results for its fourth quarter of fiscal year 2014 immediately following the close of the market on August 7, 2014.

Oplink will host a conference call and live webcast to discuss its financial results and the other matters referred to above at 2:00 p.m. Pacific Time on August 7, 2014. The conference call can be accessed by dialing 1-888-437-9445, or 1-719-457-2727 (outside the U.S. and Canada). A live webcast will be available on the Investors section of Oplink’s corporate website at www.oplink.com and via replay beginning approximately two hours after the completion of the call until Oplink’s announcement of its financial results for the next quarter. An audio replay of the call will also be available to investors beginning at approximately 5:00 p.m. Pacific Time on August 7, 2014 until 5:00 p.m. Pacific Time on August 14, 2014, by dialing 1-888-203-1112 or 1-719-457-0820 (outside the U.S. and Canada) and entering pass code 8971928#.

Cautionary Statement

This press release contains forward-looking statements, including without limitation the statements relating to (a) the possible sale of all or part of the Oplink Connected business unit, (b) intended future repurchases of the Company’s stock, (c) the planned expansion of the Company’s board of directors by up to two additional members, and (d) expected results for the fourth quarter of fiscal 2014 and expected revenue for the first quarter of fiscal 2015. These forward-looking statements involve risks and uncertainties that could cause actual future events or results to differ materially from those expressed or implied by such forward-looking statements, including the following risks and uncertainties: (1) the risk that the process being undertaken to seek the sale of the Oplink Connected business fails to identify any parties willing to acquire or invest in that business; (2) potential changes in circumstances that lead Oplink to scale back stock repurchases, such as a need for cash to fund business acquisitions; (3) the risk that the process of identifying qualified candidates interested in serving on Oplink’s board of directors is more difficult or time-consuming that expected; and (4) risks relating to Oplink’s core optical component business, including (i) possible reductions in customer orders or delays in shipments of products to customers, (ii) Oplink’s reliance on third parties to supply critical components and materials which may be in short supply, resulting in delayed shipments and lost orders, and (iii) Oplink’s increasing reliance on sales to datacom customers, which can fluctuate more than sales to our traditional telecom customers; and (iv) other risks detailed from time to time in Oplink’s periodic reports filed with the Securities and Exchange Commission, including the Company’s latest Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The foregoing information represents Oplink’s outlook only as of the date of this press release, and Oplink undertakes no obligation to update or revise any forward-looking statements, whether as a result of new developments or otherwise.

About Oplink

Oplink is a leading provider of optical communication components, intelligent modules and subsystems. We offer advanced solutions in DWDM and CWDM bandwidth creation, optical amplification, switching & routing, wavelength conditioning, monitoring & protection, connectivity and system-level integration, as well as a broad portfolio of optical transceivers for metro WDM, aggregation and access applications. We supply to global leading and emerging telecommunications, data communications and cable TV equipment makers. We are headquartered in Fremont, California and own multiple research and manufacturing facilities in Asia. To learn more about Oplink, visit our web site at www.oplink.com.

CONTACT: Steven Goldberg / Megan Bouchier / Reze Wong
         Sard Verbinnen & Co
         415-618-8750
Tuesday, July 29th, 2014 Uncategorized Comments Off on (OPLK) Announces Initiatives to Enhance Shareholder Value

(WIN) to Spin Off Assets Into Publicly Traded REIT

Transaction accelerates company’s transformation by enabling greater network investments that will enhance service to customers while providing the REIT with opportunities to grow and diversify

Aligns strategic objectives and creates new opportunities for both companies to increase shareholder value

LITTLE ROCK, Ark., July 29, 2014  — Windstream (Nasdaq:WIN), a leading provider of advanced network communications, today announced plans to spin off certain telecommunications network assets into an independent, publicly traded real estate investment trust (REIT). The transaction will enable Windstream to accelerate network investments, provide enhanced services to customers and maximize shareholder value. The transaction will allow the REIT, which will own Windstream’s existing fiber and copper network and other fixed real estate assets, to expand its network and diversify its assets through acquisitions. The company’s board of directors approved the plan following the receipt of a favorable private letter ruling from the Internal Revenue Service.

“This transaction will make Windstream a more nimble competitor in today’s increasingly dynamic communications marketplace and accelerate our deployment of advanced communications services,” said Jeff Gardner, president and CEO of Windstream. “Additionally, the REIT will have geographically diverse, high-quality assets and sustainable cash flows with the ability to grow and diversify over time.”

Transaction Rationale

The tax-free spinoff will enable Windstream to realize significant financial flexibility by lowering debt by approximately $3.2 billion and increasing free cash flow to accelerate broadband investments, transition faster to an IP network and pursue additional growth opportunities to better serve customers. As a result of the transaction, Windstream will offer faster broadband speeds and more robust performance to consumers. The company said it would expand availability of 10 Mbps Internet service to more than 80 percent of its customers by 2018. It also said it would more than double the availability of 24 Mbps Internet service by 2018, expanding to more than 30 percent of its customers.

The REIT will be positioned to provide an attractive dividend to shareholders and grow revenue through lease escalation, capital investment and acquisitions.

Transaction Details

Under the transaction, Windstream will spin off certain assets, including its fiber and copper networks and other real estate, as a REIT, which will lease use of the assets to Windstream through a long-term triple-net exclusive lease with an initial estimated rent payment of $650 million per year. Windstream will operate and maintain the assets and deliver advanced communications and technology services to consumers and businesses. Customers will see no change in their rates, scope or terms of service as a result of the transaction. Windstream will continue to have sole responsibility for meeting its existing regulatory obligations following the creation of the REIT. The REIT will focus on expanding and diversifying its assets and tenants through future acquisitions.

Windstream anticipates that the REIT will raise approximately $3.5 billion in new debt, which will be used to repay existing Windstream debt to effect the transaction. Windstream expects to retire approximately $3.2 billion of debt as part of the transaction, resulting in the company deleveraging to 3.3 times debt to adjusted operating income before depreciation and amortization immediately at closing. The company’s enhanced leverage profile and improved discretionary free cash flow will enable Windstream to invest more capital in strategic initiatives, better positioning Windstream for long-term growth.

The transaction will not result in significant operational changes at Windstream. The REIT will have approximately 25 employees. Tony Thomas, Windstream’s chief financial officer, will become CEO of the REIT. Francis X. “Skip” Frantz, a Windstream director, will serve as chairman of the REIT’s board.

“Tony has served Windstream well, and I would like to personally offer my gratitude for his many contributions over the last eight years,” Gardner said. “I am confident that his experience and expertise will benefit the REIT while also providing important continuity and fostering a close working relationship between the two companies.”

Thomas was appointed CFO in 2009. He previously served as controller for Windstream. He will continue to serve in his current role with Windstream while the company conducts a search for his successor.

“I am very excited about this new opportunity and believe that we will be able to drive additional value for shareholders and maximize benefits for customers operating as two distinct companies,” Thomas said.

Frantz has been a director of Windstream since 2006 and was chairman of the board from July 2006 to February 2010. He is a former chairman of the United States Telecom Association and was previously executive vice president of external affairs, general counsel and secretary of Alltel Corp.

“I have known Skip for many years, and his extensive telecommunications experience has been a terrific asset to me personally and to Windstream as a whole,” Gardner said. “His leadership has been integral throughout the transformation of Windstream, and he will bring significant expertise to the REIT.”

Frantz will leave the Windstream board upon close of the transaction.

Shareholder Distribution

As part of this transaction, Windstream shareholders will retain their existing shares and receive shares in the REIT commensurate with their Windstream ownership.

Dividend Practice

Windstream plans to maintain its current dividend practice through the close of the transaction. Following the spinoff, the expected annual dividend per share in the aggregate for the two companies will be $0.70 per current Windstream share, with Windstream expected to pay an annual dividend of $0.10, while the REIT will have an annual dividend equivalent to $0.60.

Approvals and Anticipated Closing

Windstream has received a private letter ruling from the Internal Revenue Service relating to certain tax matters regarding the tax-free nature of the spinoff and the qualification of the spunoff entity’s assets as real property for REIT purposes.

Completion of the proposed spinoff is contingent on receipt of regulatory approvals, final approval from the Windstream board of directors, execution of definitive documentation, and satisfaction of other customary conditions. No assurances can be given that such conditions will be satisfied or as to the timing of any regulatory action. Windstream may, at any time and for any reason until the proposed transaction is complete, abandon the spinoff or modify or change the terms of the spinoff.

Windstream anticipates that the spinoff would occur in the first quarter of 2015.

Additional Information

Bank of America Merrill Lynch and Stephens Inc. are serving as exclusive financial advisers to Windstream in the transaction. Bank of America Merrill Lynch and J.P. Morgan also are advising with respect to certain financing matters. Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal adviser to Windstream.

Conference Call

Windstream will hold a conference call at 7:30 a.m. CDT today to review the transaction.

To Access the Call:

Interested parties can access the call by dialing 1-877-374-3977, conference ID 78117902, ten minutes prior to the start time.

To Access the Call Replay:

A replay of the call will be available beginning at 10:30 a.m. CDT today and ending at midnight on Aug. 5. The replay can be accessed by dialing 1-855-859-2056, conference ID 78117902.

Webcast Information:

The conference call also will be streamed live over the company’s website at www.windstream.com/investors. Financial, statistical and other information related to the call will be posted on the site. A replay of the webcast will be available on the website beginning at 10:30 a.m. CDT today.

About Windstream

Windstream (Nasdaq:WIN), a FORTUNE 500 and S&P 500 company, is a leading provider of advanced network communications, including cloud computing and managed services, to businesses nationwide. The company also offers broadband, phone and digital TV services to consumers primarily in rural areas. For more information, visit www.windstream.com.

Cautionary Statement Regarding Forward-Looking Statements

Windstream claims the protection of the safe-harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to uncertainties that could cause actual future events and results to differ materially from those expressed in the forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the completion of the transaction, the expected benefits of the transaction, the expected financial attributes of the new Windstream and the REIT including the initial rent amount, the pro forma dividend and leverage ratio for each company, and the illustrative trading multiples and values for each company. Such statements are based on estimates, projections, beliefs and assumptions that Windstream believes are reasonable but are not guarantees of future events and results. Actual future events and results of Windstream may differ materially from those expressed in these forward-looking statements as a result of a number of important factors.

Factors that could cause actual results to differ materially from those contemplated in Windstream’s forward-looking statements include, among others:

  • risks related to the anticipated timing of the proposed separation, the expected tax treatment of the proposed transaction, the ability of each of Windstream (post-spin) and the new REIT to conduct and expand their respective businesses following the proposed spinoff, and the diversion of management’s attention from regular business concerns;
  • our ability to receive, or delays in obtaining, the regulatory approvals required to complete the spinoff; and
  • those additional factors under “Risk Factors” in Item 1A of Part I of Windstream’s Annual Report on Form 10-K for the year ended December 31, 2013, and in subsequent filings with the Securities and Exchange Commission at www.sec.gov.

In addition to these factors, actual future performance, outcomes and results may differ materially because of more general factors including, among others, general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes.

Windstream undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The foregoing review of factors that could cause Windstream’s actual results to differ materially from those contemplated in the forward-looking statements should be considered in connection with information regarding risks and uncertainties that may affect Windstream’s future results included in other filings by Windstream with the Securities and Exchange Commission at www.sec.gov.

CONTACT: Media Contact:
         David Avery, 501-748-5876
         david.avery@windstream.com

         Investor Contact:
         Mary Michaels, 501-748-7578
         mary.michaels@windstream.com
Tuesday, July 29th, 2014 Uncategorized Comments Off on (WIN) to Spin Off Assets Into Publicly Traded REIT

(MEET) Engages MKR Group for Investor Relations

MeetMe, Inc. (NASDAQ: MEET), the public market leader for social discovery, today announced that is has engaged MKR Group, Inc. as its investor relations advisor. MKR Group will assist in providing a proactive investor relations program with the goal of raising MeetMe’s exposure within the investment community and enhancing shareholder value by effectively communicating the Company’s growth opportunities and objectives.

“MKR Group has distinguished itself by its dedication to serving small cap technology companies and its deep relationships with small cap technology investors and analysts,” said David Clark, Chief Financial Officer of MeetMe. “We are excited about the significant progress and positive momentum we are making with our business, and about working with MKR Group to grow our shareholder base through increased investor awareness of our story and growth opportunities.”

About MeetMe, Inc.

MeetMe® is the leading social network for meeting new people in the US and the public market leader for social discovery (NASDAQ: MEET). MeetMe makes it easy to discover new people to chat with on mobile devices. With approximately 80 percent of traffic coming from mobile and more than one million total daily active users, MeetMe is fast becoming the social gathering place for the mobile generation. MeetMe is a leader in mobile monetization with a diverse revenue model comprising advertising, native advertising, virtual currency, and subscription. MeetMe apps are available on iPhone, iPad, and Android in multiple languages, including English, Spanish, Portuguese, French, Italian, German, Chinese (Traditional and Simplified), Russian, Japanese, Dutch, Turkish and Korean. For more information, please visit meetmecorp.com.

Cautionary Note Concerning Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including whether our investor relations program will raise our exposure within and cultivate long-term relationships with the investment community and enhance shareholder value by effectively communicating its growth opportunities and objectives, whether we will become the social gathering place for the mobile generation, and whether we will continue to make significant progress and enjoy positive momentum with our business. All statements other than statements of historical facts contained herein are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “project,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the risk that our applications will not function easily or otherwise as anticipated, the risk that we will not launch additional features and upgrades as anticipated, the risk that unanticipated events affect the functionality of our applications with popular mobile operating systems, any changes in such operating systems that degrade our mobile applications’ functionality and other unexpected issues which could adversely affect usage on mobile devices. Further information on our risk factors is contained in our filings with the Securities and Exchange Commission (“SEC”), including the Form 10-K for the year ended December 31, 2013 and the Prospectus Supplement (Rule 424(b)(5)) filed on July 24, 2014. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Tuesday, July 29th, 2014 Uncategorized Comments Off on (MEET) Engages MKR Group for Investor Relations

(SYN) States that Its Policy is Not to Comment on Unusual Market Activity

ROCKVILLE, Md., July 29, 2014  — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that in view of the unusual market activity in the Company’s stock, the NYSE MKT (the “Exchange”) has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics’ current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the development of our product candidates. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics’ forward-looking statements include, among others, the results of our development programs  not meeting our expectations and other factors described in Synthetic Biologics’ report on Form 10-K for the year ended December 31, 2013 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Tuesday, July 29th, 2014 Uncategorized Comments Off on (SYN) States that Its Policy is Not to Comment on Unusual Market Activity

(PCYC) U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications

Previously Treated Chronic Lymphocytic Leukemia (CLL) Based on Statistically Significant Progression-Free and Overall Survival Benefits Del 17P CLL, Only FDA-Approved Agent

SUNNYVALE, Calif., July 28, 2014  — Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has granted IMBRUVICA® (ibrutinib) regular (full) approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17 (del 17p CLL), including treatment naive and previously treated del 17p CLL patients.

This is the first full FDA approval for IMBRUVICA, and was granted within six months after the accelerated approval for patients with previously treated CLL in February 2014.  IMBRUVICA had received the Breakthrough Therapy Designation for patients with del 17p CLL in April 2013. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics, Inc. and Janssen Biotech, Inc.

This full approval is based on data from the Phase III RESONATE study (PCYC-1112-CA), a randomized, multi-center, international head-to-head comparison of single-agent, orally-administered IMBRUVICA versus the intravenous, monoclonal antibody ofatumumab targeting the CD 20 antigen. This study enrolled 373 patients with CLL and 18 patients with small lymphocytic lymphoma (SLL), who received at least one prior therapy. The median number of prior treatments was 2 (range, 1 to 13 treatments). At baseline, the median age of these patients was 67 years, 58% of whom had at least one tumor > 5 cm, and 32% of whom had the del 17p mutation. Patients receiving IMBRUVICA demonstrated a statistically significant improvement in progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) as compared to patients treated with ofatumumab. The median PFS and OS has not been reached on the IMBRUVICA arm. There was a 78% statistically significant reduction in the risk of progression or death as assessed by an independent review committee (IRC) according to the modified IWCLL criteria (HR 0.22, 95% CI, 0.15 to 0.32). In addition, the analysis of overall survival demonstrated a 57% statistically significant reduction in the risk of death for patients in the IMBRUVICA arm (HR 0.43; 95 CI, 0.24 to 0.79). This was observed despite a total of 57 patients who were initially randomized to ofatumumab crossing over to receive IMBRUVICA prior to the analysis. For previously treated del 17p CLL patients, there was a 75% reduction in the risk of progression or death as assessed by an IRC (HR 0.25, 95% CI, 0.14 to 0.45).

“IMBRUVICA demonstrated substantial evidence of its superiority over ofatumumab and significant benefit for previously treated CLL patients, while maintaining a favorable safety profile. This FDA approval for IMBRUVICA is a major step toward chemo-free treatment in CLL,” said John Byrd, M.D.,* Director, Division of Hematology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute and lead investigator for RESONATE. “Patients with deletion 17p CLL are at particularly high risk for poor outcomes. Today’s approval of IMBRUVICA provides these patients with the only FDA-approved treatment, regardless of whether their disease is treatment naïve or previously treated. I continue to be awed by the duration of my patients’ responses to IMBRUVICA and am grateful IMBRUVICA now is available to a broader group of CLL patients.”

CLL is a slow-growing blood cancer of the white blood cells. CLL is the most common adult leukemia in the Western world and predominately a disease of the elderly with a median age at diagnosis of 72 years.

“We are delighted IMBRUVICA has received full approval by demonstrating its ability to improve progression-free survival and, importantly, overall survival as compared to an approved standard of care, and that IMBRUVICA is now available to all patients with del 17p CLL,” said Danelle James, M.D., Vice President, Clinical Development, Pharmacyclics. “Our goal is to provide patients with clinically meaningful treatments. Thanks to the physicians and patients who helped us complete this trial in near record time, today, we have delivered on that goal by bringing IMBRUVICA to an even broader group of patients.”

Within CLL, the most commonly occurring adverse reactions (> 20%) were thrombocytopenia, neutropenia, diarrhea, anemia, upper respiratory tract infection, musculoskeletal pain, bruising, rash, fatigue, nausea, and pyrexia. Approximately 5% of patients with CLL receiving IMBRUVICA discontinued treatment due to adverse events. These included infections (2%), subdural hematoma (2%) and diarrhea (1%). Adverse events leading to dose reduction occurred in approximately 6% of patients. The Warnings and Precautions include: hemorrhage, infections, cytopenias, atrial fibrillation, secondary primary malignancies, embryo-fetal toxicities.

This approval for IMBRUVICA triggers $60 million in milestone payments to Pharmacyclics under its collaboration agreement with Janssen Biotech, Inc.

Corporate Conference Call
The Company will hold a conference call today at 11:00 AM PT. To participate in the conference call, please dial 1-877-303-7908 (domestic callers) or 1-678-373-0875 (international callers), and use conference ID number 81316392. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm.

About IMBRUVICA®
IMBRUVICA® is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton’s tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell receptor signaling complex that plays an important role in the survival and spread of malignant B cells. IMBRUVICA blocks signals that tell malignant B cells to multiply and spread uncontrollably.

IMBRUVICA was one the first medicines to receive U.S. FDA approval via the new Breakthrough Therapy Designation pathway, and is the only product to have received three Breakthrough Therapy Designations.

To date, 12 Phase III trials have been initiated with IMBRUVICA and a total of 50 trials are currently registered on www.clinicaltrials.gov. The overall clinical development program in CLL currently includes seven Phase III trials and covers all lines of therapy and various combinations of treatments. Janssen and Pharmacyclics entered a collaboration and license agreement in December 2011 to jointly develop IMBRUVICA.

Patient Access to IMBRUVICA

Patients who are prescribed IMBRUVICA can receive access support through a variety of programs:

  • The YOU&i Start™ program enables eligible patients who are experiencing insurance coverage delays to access free product for a limited time.
  • The YOU&i Access™ Instant Savings Program helps commercially insured, eligible patients who have difficulties with out-of-pocket expenses for IMBRUVICA. Eligible patients may receive support to reduce their monthly out-of-pocket costs to $25 per month.
  • The YOU&i Access Service Center assists patients with all access-related administration issues.
  • The Johnson & Johnson Patient Assistance Foundation (JJPAF), an independent, non-profit organization to which Pharmacyclics makes donations, allows patients who are deemed uninsured and eligible, and who qualify based on financial need, access to IMBRUVICA.

For more information about these comprehensive patient access programs, call or visit 1-877-877-3536 or www.IMBRUVICA.com.

About Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Leukemia (SLL)

The prevalence of CLL/SLL is approximately 115,000 patients in the United States, with approximately 16,000 newly diagnosed patients every year. As this orphan disease frequently progresses following first-line therapy, patients are faced with fewer treatment options and often are prescribed multiple lines of therapy as they relapse or become resistant to treatments.

In CLL/SLL, the genetic mutation del 17p occurs when part of chromosome 17 has been lost or deleted. CLL/SLL patients with del 17p have poor treatment outcomes. Del 17p is reported in approximately 7% of treatment-naïve CLL/SLL cases, and approximately 20% to 40% of relapsed/refractory patients harbor the mutation.

About Pharmacyclics

Pharmacyclics® is a biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify and control promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Pharmacyclics markets IMBRUVICA and has three product candidates in clinical development and five preclinical molecules in lead optimization. The company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.

Pharmacyclics (NASDAQ; PCYC) is headquartered in Sunnyvale, CA. To learn more about Pharmacyclics, please visit www.pharmacyclics.com.

INDICATIONS

IMBRUVICA is indicated to treat people with:

  • Chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
  • Chronic lymphocytic leukemia (CLL) with 17p deletion

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage – Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, hematuria, and post-procedural hemorrhage) have occurred in up to 6% of patients. Bleeding events of any grade, including bruising and petechiae, occurred in approximately half of patients treated with IMBRUVICA®.

The mechanism for the bleeding events is not well understood. IMBRUVICA® may increase the risk of hemorrhage in patients receiving anti-platelet or anti-coagulant therapies. Consider the benefit-risk of withholding IMBRUVICA® for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

Infections – Fatal and non-fatal infections have occurred with IMBRUVICA®. Twenty-six percent of patients with CLL had infections Grade 3 or greater NCI Common Terminology Criteria for Adverse Events (CTCAE). Monitor patients for fever and infections and evaluate promptly.

Cytopenias – Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 26 to 29%), thrombocytopenia (range, 10 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA®. Monitor complete blood counts monthly.

Atrial Fibrillation – Atrial fibrillation and atrial flutter (range, 6 to 9%) have occurred in patients treated with IMBRUVICA®, particularly in patients with cardiac risk factors, acute infections, and a previous history of atrial fibrillation. Periodically monitor patients clinically for atrial fibrillation. Patients who develop arrhythmic symptoms (eg, palpitations, lightheadedness) or new-onset dyspnea should have an ECG performed. If atrial fibrillation persists, consider the risks and benefits of IMBRUVICA® treatment and dose modification.

Second Primary Malignancies – Other malignancies (range, 5 to 10%) including carcinomas (range, 1 to 3%) have occurred in patients treated with IMBRUVICA®. The most frequent second primary malignancy was non-melanoma skin cancer (range, 4 to 8%).

Embryo-Fetal Toxicity – Based on findings in animals, IMBRUVICA® can cause fetal harm when administered to a pregnant woman. Advise women to avoid becoming pregnant while taking IMBRUVICA®. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

ADVERSE REACTIONS

The most common adverse reactions (>20%) in the clinical trials were thrombocytopenia (56%), neutropenia (51%), diarrhea (51%), anemia (37%), fatigue (28%), musculoskeletal pain (28%), upper respiratory tract infection (28%), rash (26%), nausea (25%), and pyrexia (24%). Approximately 5% of patients receiving IMBRUVICA® discontinued treatment due to adverse events. These included infections, subdural hematomas, and diarrhea. Adverse events leading to dose reduction occurred in approximately 6% of patients.

DRUG INTERACTIONS

CYP3A Inhibitors – Avoid concomitant administration with strong or moderate inhibitors of CYP3A. If a moderate CYP3A inhibitor must be used, reduce the IMBRUVICA® dose.

CYP3A Inducers – Avoid co-administration with strong CYP3A inducers.

SPECIFIC POPULATIONS

Hepatic Impairment – Avoid use in patients with baseline hepatic impairment.

Please see full prescribing information:  http://www.imbruvica.com/downloads/Prescribing_Information.pdf

NOTE: This announcement may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements, among others, relating to our future capital requirements, including our expected liquidity position and timing of the receipt of certain milestone payments, and the sufficiency of our current assets to meet these requirements, our future results of operations, our expectations for and timing of ongoing or future clinical trials and regulatory approvals for any of our product candidates, and our plans, objectives, expectations and intentions. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words “anticipate”, “believe”, “estimate”, “expect”, “expectation”, “goal”, “should”, “would”, “project”, “plan”, “predict”, “intend”, “target” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management’s expectations or otherwise, except as may be required by law.

* Dr. Byrd serves as national principal investigator of this Pharmacyclics-sponsored clinical study. He has served as an unpaid advisor to both Pharmacyclics and Janssen in developing the compound ibrutinib. Dr. Byrd does not have a financial interest in either company.

Contacts:

Investors
Ramses Erdtmann
Phone: 408-215-3325

Media
Samina Bari
Phone: 408-215-3169

Physicians
U.S. Medical Information
877-877-3536

Monday, July 28th, 2014 Uncategorized Comments Off on (PCYC) U.S. FDA Grants Regular (Full) Approval for IMBRUVICA® for Two Indications

(RITT) Launches Structured Cabling Solution in India

One of the First Companies to Produce a Full Range of Category 6A and 7 Cables for STP to Meet the Demanding Needs of Current and Future High-Speed Applications

BANGALORE, India, July 28, 2014  — RiT Technologies (Nasdaq:RITT), a leading provider of Structured Cabling Solutions, Intelligent Network & Infrastructure Management for enterprises and a developer of an innovative indoor optical wireless solution, today announced the launch of its structured copper cabling solutions in India.

The high performance, end-to-end structured cabling solutions include high quality cables, outlets, connectors, patch panels and adapters suited for next-generation networks and verticals across all segments.

The complete product range would be primarily available through the RiT Technologies network of system integrators and channel partners, spread across Tier I and Tier II cities at competitive price points while maximizing return on investment.

RiT Technologies’ extensive range of structured copper cabling solutions are designed with the latest advances in high-bandwidth technology to meet the infrastructure needs of enterprise markets and include: Category 6A solution, comprehensive Category 6 and CAT 5 premise wiring solution, and Category 7 copper cables. The high performance and premium quality product range of Category 6A and 7 cables for UTP / STP is assembled and tested at a RiT facility, adhering to the highest international standards. The RJ-RJ data communication patch panels and Patch-less installation for high-performance Category 6 network components are some of RiT Technologies’ unique product and service offerings.

“India is a significant market for RiT Technologies with a sophisticated IT market and tremendous potential for growth. We are committed to deliver the latest technologies, products & best business practices,” said Mr. Motti Hania, President and CEO, RiT Technologies. “Copper is the dominant form factor across key verticals in the Indian market and we will work closely with our partners in the region to provide the necessary sales tools, technical expertise, training and support to improve operations, and reduce costs for our customers,” added Mr. Hania.

RiT Technologies leads in offering a wide range of structured cabling products & solutions and has thousands of installations around the globe, including Fortune 500 companies.

About the RiT Structured Cabling Offering

RiT Technologies produces end-to-end high-performance cabling solutions that embody the latest advances in high-bandwidth technology and POE (Power over Ethernet) support.

RiT has a strong track record as an innovator in the field of cabling and intelligent network management; is a participant in the TIA cabling standard committees and participated in creating Category 6, 7 and 8 standards. RiT was also one of the first companies to produce a full range of Category 6A and & 7 cables for STP.

The RiT range of products includes both standard cabling solutions for fiber and copper (cables, outlets, connectors, patch panels and more) as well as unique innovative solutions (such as switch panels) that provide a clear advantage in terms of performance and ROI.

All RiT products are certified as component level according to TIA and ISO/IEC standards (including ANSI/TIA-568-C.2 and ISO/IEC 11801 2nd edition); are ISO 9001:2000 and ISO 14001:2004 certified, and covered by a comprehensive 20 year warranty.

RiT Technologies provides unparalleled support to its customers and partners; in terms of availability and response time and by providing direct and immediate access to our engineering workforce.

The RiT cabling products are part of the a complete range of network management solutions, geared for the next-generation networks and data centers and designed for the most complex architectures, including inter-connect and cross-connect.

To the learn more about our advanced cabling systems, please contact us at info@rittech.com.

About RiT Technologies

RiT Technologies (Nasdaq:RITT), is a leading provider of cabling, IIM and DCIM solutions and a developer of an innovative indoor optical wireless technology solution. The RiT DCIM and IIM products provide network utilization for data centers, communication rooms and work space environments. They help companies plan and provision, monitor and troubleshoot their communications networks, maximizing utilization, reliability and physical security of the network while minimizing unplanned downtime. The RiT solutions are deployed around the world, in a broad range of organizations, including data centers in corporate organizations, government agencies, financial institutions, airport authorities, healthcare and education institutions and more. Our Beamcaster™ product is an innovative indoor optical wireless networking technology solutions, designed to help customers streamline deployment, reduce infrastructure design, installation and maintenance complexity and enhance security in a cost effective way. For more information, please visit: www.rittech.com

CONTACT: COMPANY CONTACT:
         Elan Yaish, CFO
         +972-77-270-7210
         elan.yaish@rittech.com

         Investor Contacts:
         KCSA Strategic Communication
         Jeffrey Goldberger/Rob Fink
         212-896-1249/212-896-1206
         ritt@kcsa.com

         Press Contacts:
         Manish Sharma
         Tel: 98450-32618
         Email: pr_rit@infinios.in

         Web site: http://www.rittech.com
Monday, July 28th, 2014 Uncategorized Comments Off on (RITT) Launches Structured Cabling Solution in India